Dr. Kline is a medical oncologist who specializes in the treatment of patients with Hodgkin and non-Hodgkin lymphoma, including stem cell transplantation and CAR T cell therapy. He has expertise in the development and use of immunotherapy, and his lab research is focused on overcoming immune evasion pathways activated in blood cancers and on improving the effectiveness of immune-based treatments for people with lymphoma.
University of Chicago
Chicago
- Hematology/Oncology
2007
University of Chicago
Chicago
- Internal medicine
2004
University of Chicago
Chicago
M.D. - Medicine
2001
Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response.
Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response. Blood. 2025 Jan 27.
PMID: 39869833
FLT3 inhibitor maintenance after allogeneic stem cell transplantation in FLT3-mutated acute myeloid leukemia (AML) patients.
FLT3 inhibitor maintenance after allogeneic stem cell transplantation in FLT3-mutated acute myeloid leukemia (AML) patients. Ann Transl Med. 2024 Jun 10; 12(3):49.
PMID: 38911560
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma. Ann Hematol. 2024 Jan; 103(1):185-198.
PMID: 37851072
Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL.
Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL. Clin Lymphoma Myeloma Leuk. 2024 02; 24(2):83-93.
PMID: 37827881
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT.
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT. Blood Adv. 2023 02 14; 7(3):285-292.
PMID: 35851593
Antigen-Multimers: Specific, Sensitive, Precise, and Multifunctional High-Avidity CAR-Staining Reagents.
Antigen-Multimers: Specific, Sensitive, Precise, and Multifunctional High-Avidity CAR-Staining Reagents. Matter. 2021 Dec 01; 4(12):3917-3940.
PMID: 34901832
Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma.
Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma. Blood. 2021 06 17; 137(24):3454-3459.
PMID: 33881502
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma.
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Adv. 2021 03 23; 5(6):1648-1659.
PMID: 33710337
Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses.
Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses. Leuk Lymphoma. 2021 06; 62(6):1497-1501.
PMID: 33535838
Navigating Dilemmas in Treatment Choice: Our Approach to Supplemental Apheresis Prior to Enrollment in Early- Phase Cellular Therapy Clinical Trials.
Navigating Dilemmas in Treatment Choice: Our Approach to Supplemental Apheresis Prior to Enrollment in Early- Phase Cellular Therapy Clinical Trials. Transplant Cell Ther. 2021 02; 27(2):105-107.
PMID: 33781544